Background: Sexually transmitted infections are a major cause of infertility. Human papillomavirus (HPV) infection is one of the most common viral infections of the female genital tract. Only a limited number of studies have investigated the influence of HPV on fertility and its impact remains controversial. Objective: We investigated the relationship between cervical HPV infection and pregnancy outcome after intrauterine insemination (IUI). Since other sexually transmitted infections could also influence outcome, we also analyzed the influence of Trichomonas vaginalis (TV) and Chlamydia trachomatis (CT) on pregnancy outcome. Methods: We performed a retrospective analysis of 590 women who underwent 1,529 IUI cycles at AML between 2010 and 2014. Positivity of 18 different HPV types (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68) and TV was assessed by PCR in cervical cytology specimens. CT status was ascertained by detection of IgA/IgG antibodies on serum samples or by PCR on cervical swabs. Results: The HPV prevalence per IUI cycle was 11.0 and 6.9% for CT; none of the women tested positive for TV. HPV-positive women were six times less likely to become pregnant after IUI (1.87 vs. 11.36%; p = 0.0041). There was no significant difference in pregnancy rates between women with or without a history of CT (8.51 vs. 11.10%; p > 0.05). Conclusion: Detection of HPV is associated with a negative IUI outcome.

1.
Erbelding EJ: New CDC STD treatment guidelines. Hopkins HIV Rep 2002;14:1-2.
2.
Gizzo S, Ferrari B, Noventa M, Ferrari E, Patrelli TS, Gangemi M, Nardelli GB: Male and couple fertility impairment due to HPV-DNA sperm infection: update on molecular mechanism and clinical impact - systematic review. Biomed Res Int 2014;2014:230263.
3.
Depuydt CE, Jonckheere J, Berth M, Salembier GM, Vereecken AJ, Bogers JJ: Serial type-specific human papillomavirus (HPV) load measurement allows differentiation between regressing cervical lesions and serial virion productive transient infections. Cancer Med 2015, Epub ahead of print.
4.
Depuydt CE, Criel AM, Benoy IH, Arbyn M, Vereecken AJ, Bogers JJ: Changes in type-specific human papillomavirus load predict progression to cervical cancer. J Cell Mol Med 2012;16:3096-3104.
5.
Garolla A, Pizzol D, Bertoldo A, De Toni L, Barzon L, Foresta C: Association, prevalence, and clearance of human papillomavirus and antisperm antibodies in infected semen samples from infertile patients. Fertil Steril 2013;99:125-131.
6.
Foresta C, Garolla A, Zuccarello D, Pizzol D, Moretti A, Barzon L, Palù G: Human papillomavirus found in sperm head of young adult males affects the progressive motility. Fertil Steril 2010;93:802-806.
7.
Perez-Andino J, Buck CB, Ribbeck K: Adsorption of human papillomavirus 16 to live human sperm. PLoS One 2009;4:e5847.
8.
Kaspersen MD, Larsen PB, Ingerslev HJ, Fedder J, Petersen GB, Bonde J, Hollsberg P: Identification of multiple HPV types on spermatozoa from human sperm donors. PLoS One 2011;6:e18095.
9.
Rintala MA, Grenman SE, Pollanen PP, Suominen JJ, Syrjanen SM: Detection of high-risk HPV DNA in semen and its association with the quality of semen. Int J STD AIDS 2004;15:740-743.
10.
Foresta C, Patassini C, Bertoldo A, Menegazzo M, Francavilla F, Barzon L, Ferlin A: Mechanism of human papillomavirus binding to human spermatozoa and fertilizing ability of infected spermatozoa. PLoS One 2011;6: e15036.
11.
Henneberg AA, Patton WC, Jacobson JD, Chan PJ: Human papilloma virus DNA exposure and embryo survival is stage-specific. J Assist Reprod Genet 2006;23:255-259.
12.
Hermonat PL, Han L, Wendel PJ, Quirk JG, Stern S, Lowery CL, Rechtin TM: Human papillomavirus is more prevalent in first trimester spontaneously aborted products of conception compared to elective specimens. Virus Genes 1997;14:13-17.
13.
Perino A, Giovannelli L, Schillaci R, Ruvolo G, Fiorentino FP, Alimondi P, Cefalu E, Ammatuna P: Human papillomavirus infection in couples undergoing in vitro fertilization procedures: impact on reproductive outcomes. Fertil Steril 2011;95:1845-1848.
14.
Skoczynski M, Gozdzicka-Jozefiak A, Kwasniewska A: Prevalence of human papillomavirus in spontaneously aborted products of conception. Acta Obstet Gynecol Scand 2011;90:1402-1405.
15.
Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, Cunningham ML, Haupt RM: Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114:1170-1178.
16.
Matovina M, Husnjak K, Milutin N, Ciglar S, Grce M: Possible role of bacterial and viral infections in miscarriages. Fertil Steril 2004;81:662-669.
17.
Depuydt CE, Benoy IH, Beert JF, Criel AM, Bogers JJ, Arbyn M: Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of Hybrid Capture 2 for the purpose of cervical cancer screening. J Clin Microbiol 2012;50:4073-4077.
18.
Benoy IH, Vanden Broeck D, Ruymbeke MJ, Sahebali S, Arbyn M, Bogers JJ, Temmerman M, Depuydt CE: Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol 2011;205:569.e1-7.
19.
Depuydt CE, Benoy IH, Bailleul EJ, Vandepitte J, Vereecken AJ, Bogers JJ: Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 2006;17:374-381.
20.
Arbyn M, Herbert A, Schenck U, Nieminen P, Jordan J, McGoogan E, Patnick J, Bergeron C, Baldauf JJ, Klinkhamer P, Bulten J, Martin-Hirsch P: European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007;18:133-139.
21.
Micalessi IM, Boulet GA, Bogers JJ, Benoy IH, Depuydt CE: High-throughput detection, genotyping and quantification of the human papillomavirus using real-time PCR. Clin Chem Lab Med 2012;50:655-661.
22.
Depuydt CE, Boulet GA, Horvath CA, Benoy IH, Vereecken AJ, Bogers JJ: Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med 2007;11:881-891.
23.
Depuydt CE, Leuridan E, Van Damme P, Bogers J, Vereecken AJ, Donders GG: Epidemiology of Trichomonas vaginalis and human papillomavirus infection detected by real-time PCR in Flanders. Gynecol Obstet Invest 2010;70:273-280.
24.
Caliendo AM, Jordan JA, Green AM, Ingersoll J, Diclemente RJ, Wingood GM: Real-time PCR improves detection of Trichomonas vaginalis infection compared with culture using self-collected vaginal swabs. Infect Dis Obstet Gynecol 2005;13:145-150.
25.
Kengne P, Veas F, Vidal N, Rey JL, Cuny G: Trichomonas vaginalis: repeated DNA target for highly sensitive and specific polymerase chain reaction diagnosis. Cell Mol Biol (Noisy-le-Grand) 1994;40:819-831.
26.
World Health Organization: WHO Laboratory Manual for the Examination and Processing of Human Semen, ed 5. Geneva, WHO Press, 2010.
27.
Schoonjans F, Zalata A, Depuydt CE, Comhaire FH: MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed 1995;48:257-262.
28.
Arbyn M, Fabri V, Temmerman M, Simoens C: Attendance at cervical cancer screening and use of diagnostic and therapeutic procedures on the uterine cervix assessed from individual health insurance data (Belgium, 2002-2006). PLoS One 2014;9:e92615.
29.
Strehler E, Sterzik K, Malthaner D, Hoyer H, Nindl I, Schneider A: Influence of ovarian stimulation on the detection of human papillomavirus DNA in cervical scrapes obtained from patients undergoing assisted reproductive techniques. Fertil Steril 1999;71:815-820.
30.
Conde-Ferraez L, Chan May AA, Carrillo-Martinez JR, Ayora-Talavera G, Gonzalez-Losa MR: Human papillomavirus infection and spontaneous abortion: a case-control study performed in Mexico. Eur J Obstet Gynecol Reprod Biol 2013;170:468-473.
31.
Syrjanen S, Waterboer T, Sarkola M, Michael K, Rintala M, Syrjanen K, Grenman S, Pawlita M: Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol 2009;90:1515-1526.
32.
Buchinsky FJ, Carter JJ, Wipf GC, Hughes JP, Koutsky LA, Galloway DA: Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women. J Clin Virol 2006;35:450-453.
33.
Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA: Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-1919.
34.
Stanley M: HPV - immune response to infection and vaccination. Infect Agent Cancer 2010;5:19.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.